L-EPC Substrate for Nuclear Reprogramming Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for nuclear reprogramming of human skin fibroblasts into induced Pluripotent Stem Cells (iPSCs face challenges such as low efficiency, genomic instability, and the need for invasive procedures, along with limitations in using other cell types like T-cells and hematopoietic stem cells due to genomic rearrangements and accessibility issues.
Innovation Solution
Late-outgrowth endothelial progenitor cells (L-EPCs) are used as a reprogramming substrate, which can be efficiently reprogrammed with minimal manipulation, are free from major genomic rearrangements, and can be obtained from blood samples, facilitating high-throughput and standardized nuclear reprogramming.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If skin fibroblasts are used as cellular substrate for reprogramming, then the procedure is non-invasive and easily accessible, but the reprogramming efficiency is low and kinetics are slow
Solution Approach 1:
The patent changes the cellular substrate parameter from skin fibroblasts to late outgrowth endothelial progenitor cells (LEPCs) isolated from peripheral blood. This parameter change resolves the contradiction by providing a cell type that maintains ease of accessibility through routine blood sampling while dramatically improving reprogramming efficiency and kinetics, as LEPCs possess a more permissive epigenetic state that facilitates rapid reprogramming.
Solution Approach 2:
The patent segments the blood cell population to specifically isolate LEPCs from other blood cells through a multi-step process involving CD34+ cell selection and culture conditions that enrich for LEPCs. This segmentation allows obtaining the high-efficiency reprogramming substrate from routine blood samples without requiring invasive procedures.
2Ease of operation
If T-cells or myeloid cells from peripheral blood are used for reprogramming, then invasive procedures are avoided, but the cells possess permanent genomic rearrangements that limit their utility
Solution Approach 1:
The patent changes the cellular substrate parameter from T-cells or myeloid cells to LEPCs isolated from peripheral blood. This parameter change resolves the contradiction by selecting a cell type that maintains the advantage of non-invasive blood sampling while possessing a stable genome without the permanent rearrangements characteristic of T-cell receptors or immunoglobulin genes, making the resulting iPSCs suitable for clinical applications.
3Productivity
If bone marrow derived hematopoietic stem cells are used for reprogramming, then reprogramming efficiency is high, but invasive bone marrow aspiration is required
Solution Approach 1:
The patent applies universality by demonstrating that LEPCs isolated from routine peripheral blood samples can serve as an alternative substrate that achieves high reprogramming efficiency comparable to bone marrow derived cells. This multi-functional approach allows obtaining high-efficiency reprogramming substrates through the universally applicable routine blood draw procedure rather than the specialized invasive bone marrow aspiration.
Solution Approach 2:
The patent changes the source location parameter from bone marrow to peripheral blood, specifically isolating LEPCs from the circulating blood compartment. This parameter change resolves the contradiction by providing a non-invasive access route to obtain cells with high reprogramming potential, as LEPCs possess a more permissive epigenetic state that facilitates efficient reprogramming.
4Productivity
If chemical enhancers are included in reprogramming protocols to increase efficiency, then reprogramming efficiency improves, but the protocol complexity increases and manipulation of cellular substrate increases
Solution Approach 1:
The patent changes the cellular substrate parameter to LEPCs, which inherently possess a more permissive epigenetic state that facilitates reprogramming. This parameter change resolves the contradiction by providing a cell type that achieves high reprogramming efficiency through its intrinsic properties rather than requiring complex chemical enhancer cocktails, thereby simplifying the overall protocol while maintaining high productivity.
Data Source
AI summary
This invention relates to the use of late out-growth endothelial progenitor cells (L-EPCs) as a cellular substrate for the generation of Induced pluripotent stem cells (iPSCs). This may be useful in the production of patient-specific tissues for disease modelling, drug and toxicology screening, tissue replacement and delivery of gene therapy.